Latest News

by

Read the Open Letter here We are proud to support this open letter to congress encouraging representatives to pass the FDA Modernization Act.  Originally passed in 1938, the Federal Food, Drug, and Cosmetics Act (FFDCA) was … Read More

by

1) Validates use of Human-on-a-Chip system to mimic disease mechanisms of rare autoimmune neuropathies that cannot be replicated in animal models.

2) Efficacy data from microphysiological system supported the authorization of a clinical study (NCT04658472) in 2021 through collaboration with Sanofi.

Using Human-on-a-Chip technology to reduce animal testing in drug discovery
by

Senior Editor with Pharma Manufacturing interviews Hesperos executives Michael Shuler and Nathan Post on the rise of Human-on-a-Chip (HoaC) systems and how they are replacing the need for animal testing in drug discovery.

fellow
by

Dr. James J. Hickman elected as Fellow of the National Acadamy of Inventors Hesperos is excited to announce that Chief Scientist, Dr. James J. Hickman, has been elected fellow of the National Academy of Inventors (NAI).  … Read More

human-on-a-chip
by

Presentation Highlights

This is a company overview presentation given by Dr. James Hickman at this years Florida Simulation Summit 2020 in October.  Learn more about the technology and exciting path ahead. Key highlights from the presentation include:

  • A brief history of Hesperos
  • How the Human-on-a-Chip technology works and the current state of the technology
  • Key applications and path forward

Human-on-a-Chip®

Functional in vitro models that accurately predict how new drug candidates will impact the human body – something that has previously required animal testing or human clinical trials to determine.

What’s on each Chip?

Systemic toxicology models with interlinked organs, including: heart, liver, lung, brain, skin, muscle, GI tract, kidney, pancreas, endocrine, bone marrow and the neuromuscular junction in a serum free, recirculating medium utilizing a pumpless platform.